- Current report filing (8-K)
08 October 2010 - 7:59AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 7, 2010
ONYX PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
DELAWARE
(State of incorporation)
|
|
0-28298
(Commission File No.)
|
|
94-3154463
(IRS Employer Identification No.)
|
2100 Powell Street
Emeryville, California 94608
(Address of principal executive offices and zip code)
Registrants telephone number, including area code:
(510) 597-6500
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
o
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
o
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
o
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
o
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
ITEM 8.01 OTHER EVENTS.
On October 7, 2010, Onyx Pharmaceuticals, Inc. provided an update regarding its
development plans for carfilzomib, announcing in a press release that it will be delaying the New Drug Application
filing for accelerated approval of carfilzomib based on routine recent discussions with the
Chemistry, Manufacturing and Controls reviewing division of the U.S. Food and Drug
Administration. A copy of the press release, titled Onyx Pharmaceuticals Provides Status Update
on Carfilzomib is attached as Exhibit 99.1 hereto and is incorporated herein by reference.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
|
|
|
Number
|
|
Description
|
|
|
|
99.1
|
|
Press release, dated October 7, 2010, titled Onyx Pharmaceuticals Provides Status Update
on Carfilzomib
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
ONYX PHARMACEUTICALS, INC.
|
|
Dated: October 7, 2010
|
|
|
|
|
By:
|
/s/ Suzanne M. Shema
|
|
|
|
Suzanne M. Shema
|
|
|
|
Senior Vice President, General Counsel
|
|
|
EXHIBIT INDEX
|
|
|
Number
|
|
Description
|
|
|
|
99.1
|
|
Press release, dated October 7, 2010, titled Onyx Pharmaceuticals Provides Status Update
on Carfilzomib
|
Onyx Pharmaceuticals, Inc. (MM) (NASDAQ:ONXX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Onyx Pharmaceuticals, Inc. (MM) (NASDAQ:ONXX)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Onyx Pharmaceuticals, Inc. (MM) (NASDAQ): 0 recent articles
More News Articles